5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Inhibitory effects of Kratom constituents, mitragynine and 7-hydroxymitragynine, on 4-methylumbelliferone glucuronidation by human UDP-glucuronosyltransferases

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          As Kratom use increases, concerns about potential herb-drug interactions with liver enzymes, particularly UDP-glucuronosyltransferases (UGTs), have emerged. This study investigated the inhibitory effects of Kratom leaf constituents, mitragynine and 7-hydroxymitragynine, on 4-methylumbelliferone (4MU) glucuronidation by a panel of recombinant human UGT enzymes, including UGT1A1, UGT1A3, UGT1A6, UGT1A9, UGT2B7, and UGT2B15. The degree of inhibition exhibited by mitragynine and 7-hydroxymitragynine on UGTs varied. Mitragynine exhibited the highest inhibitory potency on UGT1A3 with an IC 50 value of 72 µM. Moderate inhibition potency of mitragynine were observed for UGT1A6, UGT1A9 and UGT2B15, with IC 50 value of 121, 131, and 152 µM, respectively, whereas the inhibition on UGT1A1 and UGT2B7 was low (IC 50 > 200 µM). 7-Hydroxymitragynine exhibited the highest inhibitory potency on UGT1A9, with IC 50 value of 51 µM, while moderate potency was observed for UGT1A1 and UGT1A3, with IC 50 value of 196 and 141 µM, respectively. The inhibitory potency of 7-hydroxymitragynine on UGT2B15 was low (IC 50 > 200 µM), while negligible effects were observed for UGT1A6 and UGT2B7. Kinetic inhibition study revealed that mitragynine noncompetitively inhibited UGT1A3 (K i = 45 µM) and competitively inhibited UGT1A9 (K i = 114 µM), while 7-hydroxymitragynine competitively inhibited UGT1A3 (K i = 33 µM) and noncompetitively inhibited UGT1A9 (K i = 29 µM). The experimental K i values found here are relatively high compared to the maximum plasma concentrations of mitragynine and 7-hydroxymitragynine reported in humans, suggesting an unlikely potential for herb-drug interactions via UGT inhibition.

          Graphical Abstract

          Highlights

          • As Kratom use rises, concerns grow about its potential herb-drug interactions with UGTs.

          • The inhibition degree by mitragynine and 7-hydroxymitragynine on UGTs varied.

          • Mitragynine showed potential in vitro inhibition on UGT1A3, and 7-hydroxymitragynine on UGT1A9.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification.

          Human UDP-glucuronosyltransferase (UGT) exists as a superfamily of 22 proteins, which are divided into 5 families and 6 subfamilies on the basis of sequence identity. Members of the UGT1A and 2B subfamilies play a key role in terminating the biological actions and enhancing the renal elimination of non-polar (lipophilic) drugs from all therapeutic classes. These enzymes primarily catalyse the covalent linkage of glucuronic acid, derived from the cofactor UDP-glucuronic acid, to a substrate with a suitable acceptor functional group. This process is referred to as glucuronidation. While the liver is the major detoxification organ, and as such contains the greatest abundance and diversity of UGTs, these enzymes also exhibit significant, but variable extra-hepatic expression. This review discusses recent advances in the understanding of the functional roles of UGT, their regulation and tissue expression, and clinical significant factors (ontogeny, interactions and polymorphisms) that affect glucuronidation activity in humans. Copyright © 2013 Elsevier Ltd. All rights reserved.
            • Record: found
            • Abstract: found
            • Article: not found

            From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction.

            Kratom (or Ketum) is a psychoactive plant preparation used in Southeast Asia. It is derived from the plant Mitragyna speciosa Korth. Kratom as well as its main alkaloid, mitragynine, currently spreads around the world. Thus, addiction potential and adverse health consequences are becoming an important issue for health authorities. Here we reviewed the available evidence and identified future research needs. It was found that mitragynine and M. speciosa preparations are systematically consumed with rather well defined instrumentalization goals, e.g. to enhance tolerance for hard work or as a substitute in the self-treatment of opiate addiction. There is also evidence from experimental animal models supporting analgesic, muscle relaxant, anti-inflammatory as well as strong anorectic effects. In humans, regular consumption may escalate, lead to tolerance and may yield aversive withdrawal effects. Mitragynine and its derivatives actions in the central nervous system involve μ-opioid receptors, neuronal Ca²⁺ channels and descending monoaminergic projections. Altogether, available data currently suggest both, a therapeutic as well as an abuse potential. Copyright © 2012 Elsevier Ltd. All rights reserved.
              • Record: found
              • Abstract: found
              • Article: not found

              Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects.

              Kratom (Mitragyna speciosa) is a plant indigenous to Thailand and Southeast Asia. Kratom leaves produce complex stimulant and opioid-like analgesic effects. In Asia, kratom has been used to stave off fatigue and to manage pain, diarrhea, cough, and opioid withdrawal. Recently, kratom has become widely available in the United States and Europe by means of smoke shops and the Internet. Analyses of the medical literature and select Internet sites indicate that individuals in the United States are increasingly using kratom for the self-management of pain and opioid withdrawal. Kratom contains pharmacologically active constituents, most notably mitragynine and 7-hydroxymitragynine. Kratom is illegal in many countries. Although it is still legal in the United States, the US Drug Enforcement Administration has placed kratom on its "Drugs and Chemicals of Concern" list. Physicians should be aware of the availability, user habits, and health effects of kratom. Further research on the therapeutic uses, toxic effects, and abuse potential of kratom and its constituent compounds are needed.

                Author and article information

                Contributors
                Journal
                Toxicol Rep
                Toxicol Rep
                Toxicology Reports
                Elsevier
                2214-7500
                10 February 2025
                June 2025
                10 February 2025
                : 14
                : 101951
                Affiliations
                [0005]Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand
                Author notes
                [* ]Correspondence to: Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand. veruch@ 123456kku.ac.th
                Article
                S2214-7500(25)00069-1 101951
                10.1016/j.toxrep.2025.101951
                11872117
                40026476
                3b7f79b1-3394-43d6-abf5-865145bea730
                © 2025 The Authors

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                : 26 December 2024
                : 21 January 2025
                : 4 February 2025
                Categories
                Article

                glucuronidation,herb-drug interaction,7-hydroxymitragynine,kratom,mitragynine,udp-glucuronosyltransferases

                Comments

                Comment on this article

                Related Documents Log